Current/JJ
Status/NN
,/,
Challenges/NNS
,/,
Policies/NNS
,/,
and/CC
Bioethics/NNS
of/IN
Biobanks/NNS
./.
====================
Many/JJ
biobanks/NNS
were/VBD
established/VBN
as/IN
biorepositories/NNS
for/IN
biomedical/JJ
research/NN
,/,
and/CC
a/DT
number/NN
of/IN
biobanks/NNS
were/VBD
founded/VBN
in/IN
the/DT
1990s/NN
./.
====================
The/DT
main/JJ
aim/NN
of/IN
the/DT
biobank/NN
is/VBZ
to/TO
store/VB
and/CC
to/TO
maintain/VB
biomaterials/NNS
for/IN
studying/VBG
chronic/JJ
disease/NN
,/,
identifying/VBG
risk/NN
factors/NNS
of/IN
specific/JJ
diseases/NNS
,/,
and/CC
applying/VBG
personalized/VBN
drug/NN
therapies/NNS
./.
====================
This/DT
report/NN
provides/VBZ
a/DT
review/NN
of/IN
biobanks/NNS
,/,
including/VBG
Korean/JJ
biobanks/NNS
and/CC
an/DT
analysis/NN
of/IN
sample/JJ
volumes/NNS
,/,
regulations/NNS
,/,
policies/NNS
,/,
and/CC
ethical/JJ
issues/NNS
of/IN
the/DT
biobank/NN
./.
====================
Until/IN
now/RB
,/,
the/DT
top/NN
6/CD
countries/NNS
according/VBG
to/TO
the/DT
number/NN
of/IN
large-scale/JJ
biobanks/VBZ
are/VBP
the/DT
United/JJ
Kingdom/NN
,/,
United/JJ
States/NNS
,/,
Sweden/JJ
,/,
France/NN
,/,
the/DT
Netherlands/NNS
,/,
and/CC
Italy/RB
,/,
and/CC
there/EX
is/VBZ
one/CD
major/JJ
National/JJ
Biobank/NNP
of/IN
Korea/NN
(/(
NBK/NN
)/)
and/CC
17/CD
regional/JJ
biobanks/NNS
in/IN
Korea/NN
./.
====================
Many/JJ
countries/NNS
have/VBP
regulations/NNS
and/CC
guidelines/NNS
for/IN
the/DT
biobanks/NNS
,/,
and/CC
the/DT
importance/NN
of/IN
good/JJ
management/NN
of/IN
biobanks/NNS
is/VBZ
increasing/VBG
./.
====================
Meanwhile/DT
,/,
according/VBG
to/TO
a/DT
first/JJ
survey/NN
of/IN
456/CD
biobank/NN
managers/NNS
in/IN
the/DT
United/JJ
States/NNS
,/,
biobankers/NNS
are/VBP
concerned/VBN
with/IN
the/DT
underuse/JJ
of/IN
the/DT
samples/NNS
in/IN
their/PRP$
repositories/NNS
,/,
which/WDT
need/VBD
to/TO
be/VB
advertised/VBN
for/IN
researchers/NNS
./.
====================
Korea/NN
Biobank/NN
Network/NN
(/(
KBN/NN
)/)
project/VBP
phase/NN
II/CD
(/(
2013-2015/CD
)/)
was/VBD
also/RB
planned/VBD
for/IN
the/DT
promotion/NN
to/TO
use/VB
biospecimens/NNS
in/IN
the/DT
KBN/NN
./.
====================
The/DT
KBN/NN
is/VBZ
continuously/RB
introducing/VBG
for/IN
researchers/NNS
to/TO
use/VB
biospecimens/NNS
in/IN
the/DT
biobank/NN
./.
====================
An/DT
accreditation/NN
process/NN
can/MD
also/RB
be/VB
introduced/VBN
for/IN
biobanks/NNS
to/TO
harmonize/VB
collections/NNS
and/CC
encourage/VBP
use/NN
of/IN
biospecimens/NNS
in/IN
the/DT
biobanks/NNS
./.
====================
KBN/NN
is/VBZ
preparing/VBG
an/DT
on-line/JJ
application/NN
system/NN
for/IN
the/DT
distribution/NN
of/IN
biospecimens/NNS
and/CC
a/DT
biobank/NN
accreditation/NN
program/NN
and/CC
is/VBZ
trying/VBG
to/TO
harmonize/VB
the/DT
biobanks/NNS
./.
====================
Biobanks/NNS
provide/VBP
important/JJ
materials/NNS
for/IN
many/JJ
research/NN
realms/NNS
,/,
such/JJ
as/IN
biomarker/NN
development/NN
for/IN
the/DT
early/JJ
diagnoses/NNS
of/IN
specific/JJ
diseases/NNS
,/,
including/VBG
cancer/NN
and/CC
genetic/JJ
diseases/NNS
,/,
and/CC
for/IN
applying/VBG
personalized/VBN
drug/NN
therapies/NNS
./.
====================
There/EX
is/VBZ
no/DT
consensus/NN
definition/NN
for/IN
a/DT
biobank/NN
,/,
but/CC
it/PRP
is/VBZ
considered/VBN
a/DT
biorepository/JJ
that/DT
stores/NNS
biospecimens/NNS
for/IN
use/NN
for/IN
diagnostic/JJ
or/CC
research/NN
purposes/NNS
./.
====================
Also/RB
,/,
a/DT
biobank/NN
is/VBZ
an/DT
institution/NN
that/DT
collects/VBZ
,/,
stores/NNS
,/,
processes/NNS
,/,
and/CC
uses/VBZ
biological/JJ
materials/NNS
,/,
genetic/JJ
data/NNS
,/,
and/CC
associated/VBN
epidemiological/JJ
data/NNS
from/IN
human/JJ
beings/NNS
or/CC
distributes/VBZ
them/PRP
to/TO
researchers/NNS
[/(
1/CD
]/)
./.
====================
The/DT
term/NN
``/NN
research/NN
biobank/NN
''/CD
means/NNS
a/DT
collection/NN
of/IN
human/JJ
biological/JJ
material/NN
and/CC
data/NNS
obtained/VBN
directly/RB
by/IN
the/DT
analysis/NN
of/IN
this/DT
material/JJ
,/,
which/WDT
is/VBZ
used/VBN
or/CC
is/VBZ
to/TO
be/VB
used/VBN
for/IN
research/NN
purposes/NNS
[/(
2/CD
]/)
./.
====================
A/DT
repository/JJ
is/VBZ
defined/VBN
as/IN
an/DT
organization/NN
,/,
place/NN
,/,
room/JJ
,/,
or/CC
physical/JJ
entity/NN
that/DT
may/MD
receive/VB
,/,
process/NN
,/,
store/RB
,/,
maintain/VBP
,/,
and/or/CC
distribute/JJ
specimens/NNS
,/,
their/PRP$
derivatives/NNS
,/,
and/CC
their/PRP$
associated/VBN
data/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
provide/VBP
a/DT
review/NN
of/IN
biobanks/NNS
,/,
including/VBG
Korean/JJ
biobanks/NNS
and/CC
an/DT
analysis/NN
of/IN
sample/JJ
volumes/NNS
,/,
regulations/NNS
,/,
policies/NNS
,/,
and/CC
ethical/JJ
issues/NNS
of/IN
the/DT
biobank/NN
./.
====================
The/DT
oldest/JJS
biobank/NN
for/IN
the/DT
Framingham/NN
Heart/NN
Study/NN
(/(
FHS/NN
)/)
,/,
funded/VBD
by/IN
the/DT
National/JJ
Institute/JJ
of/IN
Health-National/JJ
Heart/NN
,/,
Lung/NN
,/,
and/CC
Blood/NN
Institute/JJ
(/(
NIH-NHLBI/NN
)/)
,/,
collects/NNS
blood/NN
samples/NNS
and/CC
data/NNS
and/CC
was/VBD
established/VBN
in/IN
1948/CD
./.
====================
The/DT
purpose/NN
of/IN
the/DT
Framingham/NN
program/NN
was/VBD
the/DT
development/NN
of/IN
case-finding/JJ
procedures/NNS
./.
====================
A/DT
total/JJ
of/IN
5,209/CD
persons/NNS
between/IN
the/DT
age/NN
of/IN
30/CD
and/CC
62/CD
from/IN
Framingham/JJ
,/,
Massachusetts/NNS
participated/JJ
in/IN
this/DT
study/NN
,/,
and/CC
three/CD
generations/NNS
of/IN
participants/NNS
(/(
for/IN
a/DT
total/JJ
of/IN
almost/RB
15,000/CD
participants/NNS
)/)
were/VBD
recruited/VBN
;/:
the/DT
researchers/NNS
began/VBD
clinical/JJ
examinations/NNS
and/CC
lifestyle-related/JJ
interviews/VBZ
to/TO
seek/VB
risk/NN
factors/NNS
related/JJ
to/TO
cardiovascular/JJ
disease/NN
(/(
CVD/NN
)/)
development/NN
./.
====================
FHS/NN
has/VBZ
revealed/VBN
the/DT
significant/JJ
identification/NN
of/IN
the/DT
main/JJ
CVD/NN
risk/NN
factors/NNS
,/,
such/JJ
as/IN
high/JJ
blood/NN
pressure/NN
,/,
high/JJ
blood/NN
cholesterol/NN
,/,
smoking/VBG
,/,
and/CC
obesity/NN
,/,
as/IN
well/RB
as/IN
immense/JJ
information/NN
on/IN
factors/NNS
,/,
such/JJ
as/IN
blood/NN
triglyceride/NN
and/CC
high-density/JJ
lipoprotein/NN
cholesterol/NN
levels/NNS
,/,
age/NN
,/,
and/CC
so/RB
on/IN
[/(
3/CD
]/)
./.
====================
By/IN
the/DT
late/JJ
1990s/CD
,/,
scientists/VBZ
realized/VBD
that/IN
some/DT
diseases/NNS
originated/VBN
from/IN
a/DT
single/JJ
defective/JJ
gene/NN
,/,
but/CC
most/JJS
genetic/JJ
diseases/NNS
are/VBP
caused/VBN
by/IN
multiple/JJ
genetic/JJ
factors/NNS
on/IN
multiple/JJ
genes/NNS
[/(
4/CD
]/)
./.
====================
For/IN
an/DT
understanding/NN
of/IN
whole-genome/JJ
information/NN
of/IN
humans/NNS
,/,
the/DT
Human/JJ
Genome/NN
Project/JJ
(/(
HGP/NN
)/)
was/VBD
begun/VBN
in/IN
1990/CD
,/,
and/CC
the/DT
human/JJ
genome/NN
was/VBD
completely/RB
released/VBD
in/IN
2003/CD
./.
====================
Owing/VBG
to/TO
the/DT
increased/VBN
demands/VBZ
on/IN
qualified/VBN
biospecimens/NNS
for/IN
research/NN
,/,
the/DT
number/NN
of/IN
biobanks/NNS
has/VBZ
increased/VBN
significantly/RB
between/IN
1980/CD
and/CC
1999/CD
worldwide/NN
[/(
5/CD
]/)
./.
====================
Many/JJ
countries/NNS
,/,
including/VBG
the/DT
European/JJ
countries/NNS
,/,
Japan/NNP
,/,
and/CC
Korea/NN
,/,
have/VBP
established/VBN
large-scale/JJ
biobanks/VBZ
to/TO
collect/VB
a/DT
large/JJ
quantity/NN
of/IN
patient/NN
specimens/NNS
from/IN
over/IN
200,000/CD
people/JJ
,/,
based/VBN
on/IN
their/PRP$
population/NN
and/or/CC
on/IN
their/PRP$
disease-oriented/JJ
groups/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Until/IN
now/RB
,/,
the/DT
top/NN
6/CD
countries/NNS
,/,
according/VBG
to/TO
the/DT
number/NN
of/IN
large-scale/JJ
biobanks/VBZ
,/,
have/VBP
been/VBN
the/DT
United/JJ
Kingdom/NN
(/(
n/NN
=/JJ
15/CD
)/)
,/,
United/JJ
States/NNS
(/(
n/NN
=/JJ
14/CD
)/)
,/,
Sweden/JJ
(/(
n/NN
=/JJ
12/CD
)/)
,/,
France/NN
(/(
n/NN
=/JJ
9/CD
)/)
,/,
the/DT
Netherlands/NNS
(/(
n/NN
=/JJ
8/CD
)/)
,/,
and/CC
Italy/RB
(/(
n/NN
=/JJ
8/CD
)/)
./.
====================
Seventy/NN
percent/NN
of/IN
the/DT
world/NN
's/POS
biobanks/NNS
are/VBP
located/JJ
in/IN
Europe/NN
./.
====================
Sixty/NN
percent/JJ
of/IN
sponsors/NNS
for/IN
biobanks/NNS
are/VBP
governmental/JJ
or/CC
national/JJ
institutes/NNS
,/,
and/CC
16/CD
%/NN
to/TO
17/CD
%/NN
of/IN
biobanks/NNS
are/VBP
sponsored/VBN
by/IN
non-profit/JJ
public/JJ
service/RB
corporations/NNS
,/,
universities/NNS
,/,
and/CC
hospitals/NNS
./.
====================
The/DT
number/NN
of/IN
biobanks/NNS
is/VBZ
increasing/VBG
recently/RB
,/,
and/CC
particularly/RB
,/,
43/CD
biobanks/NNS
were/VBD
launched/VBN
in/IN
the/DT
2000s/NN
./.
====================
Most/JJS
biobanks/NNS
(/(
60/CD
%/NN
)/)
recruited/VBN
less/RBR
than/IN
100,000/CD
people/NN
and/CC
thirty/NN
percents/NNS
of/IN
the/DT
biobanks/NNS
recruited/VBN
100,000/CD
to/TO
1,000,000/CD
people/NN
./.
====================
The/DT
number/NN
of/IN
biobanks/NNS
collecting/JJ
blood/NN
is/VBZ
35/CD
;/:
35/CD
collect/NN
other/JJ
biofluids/NNS
,/,
43/CD
collect/JJ
biomaterials/NNS
,/,
and/CC
16/CD
secure/NN
tissue/NN
[/(
6/CD
]/)
./.
====================
In/IN
2005/CD
,/,
the/DT
UK/NN
Biobank/NN
started/VBD
collecting/JJ
DNA/NN
samples/NNS
and/CC
personal/JJ
information/NN
from/IN
500,000/CD
volunteers/NNS
aged/JJ
between/IN
45/CD
and/CC
69/CD
years/NNS
./.
====================
The/DT
main/JJ
purpose/NN
of/IN
the/DT
UK/NN
Biobank/NN
is/VBZ
to/TO
look/VB
for/IN
the/DT
relationship/NN
between/IN
disease/NN
,/,
lifestyle/JJ
,/,
and/CC
genes/NNS
,/,
as/IN
well/RB
as/IN
to/TO
identify/VB
risk/NN
factors/NNS
that/WDT
affect/VBP
individual/JJ
response/NN
to/TO
specific/JJ
drug/NN
treatment/NN
./.
====================
The/DT
UK/NN
Biobank/NN
has/VBZ
collected/VBN
biospecimens/NNS
from/IN
500,000/CD
people/JJ
between/IN
2006/CD
and/CC
2010/CD
,/,
and/CC
they/PRP
provided/VBD
their/PRP$
specimens/NNS
to/TO
researchers/NNS
starting/VBG
from/IN
March/JJ
2012/CD
[/(
7/CD
,/,
8/CD
]/)
./.
====================
In/IN
2008/CD
,/,
United/JJ
States/NNS
researchers/NNS
stored/VBD
270/CD
million/NN
specimens/NNS
in/IN
biobanks/NNS
,/,
and/CC
the/DT
rate/NN
of/IN
new/JJ
sample/NN
collection/NN
is/VBZ
20/CD
million/NN
per/FW
year/NN
[/(
9/CD
]/)
./.
====================
In/IN
2009/CD
,/,
Time/JJ
magazine/NN
chose/NN
biobanking/VBG
as/IN
one/CD
of/IN
the/DT
10/CD
ideas/IN
``/CD
changing/VBG
the/DT
world/NN
right/JJ
now/RB
''/RB
[/(
10/CD
]/)
./.
====================
Elger/RBR
and/CC
Caplan/NN
[/(
11/CD
]/)
demonstrated/VBD
that/IN
the/DT
challenge/NN
produced/VBD
by/IN
biobanks/NNS
is/VBZ
immense/JJ
:/:
after/IN
more/RBR
than/IN
50/CD
years/NNS
of/IN
classical/JJ
health/NN
research/NN
ethics/NNS
,/,
regulatory/JJ
agencies/NNS
have/VBP
begun/VBN
to/TO
question/NN
fundamental/JJ
ethical/JJ
milestones/NNS
./.
====================
A/DT
new/JJ
report/NN
by/IN
Visiongain/JJ
(/(
http/NN
:/:
//www.visiongain.com/IN
)/)
,/,
a/DT
business/JJ
information/NN
provider/IN
based/VBN
in/IN
London/JJ
,/,
UK/NN
,/,
predicts/VBZ
the/DT
world/NN
market/NN
for/IN
biobanking/VBG
on/IN
human/JJ
medicine/NN
will/MD
generate/VB
$/NN
24.4/CD
bn/IN
in/IN
2017/CD
and/CC
expand/CC
strongly/RB
to/TO
2023/CD
./.
====================
In/IN
1995/CD
,/,
the/DT
Ministry/NN
of/IN
Education/NN
and/CC
Science/NN
Technology/NN
established/VBN
the/DT
Korea/NN
National/JJ
Research/NN
Resource/NN
Centers/NNS
for/IN
collecting/JJ
various/JJ
bioresources/NNS
./.
====================
However/RB
,/,
the/DT
scale/NN
and/CC
variety/NN
of/IN
the/DT
collections/NNS
were/VBD
lacking/VBG
,/,
because/IN
collections/NNS
were/VBD
based/VBN
on/IN
an/DT
individual/JJ
research/NN
project/VB
./.
====================
The/DT
Ministry/NN
of/IN
Environment/JJ
established/VBN
biobanks/NNS
,/,
but/CC
their/PRP$
samples/NNS
were/VBD
limited/VBN
to/TO
specimens/NNS
needed/VBD
for/IN
the/DT
research/NN
of/IN
environmentally/RB
induced/VBD
diseases/NNS
./.
====================
Therefore/RB
,/,
there/EX
was/VBD
a/DT
necessity/NN
to/TO
establish/VB
a/DT
biobank/NN
that/DT
was/VBD
centered/JJ
on/IN
hospitals/NNS
for/IN
collecting/JJ
human/JJ
biospecimens/NNS
[/(
12/CD
]/)
./.
====================
In/IN
2008/CD
,/,
the/DT
Ministry/NN
of/IN
Health/NN
and/CC
Welfare/JJ
started/VBD
the/DT
Korea/NN
Biobank/NNP
Project/JJ
(/(
KBP/NN
)/)
and/CC
tried/VBD
to/TO
support/VB
establishing/VBG
biobanks/VBZ
within/IN
university-affiliated/JJ
general/JJ
hospitals/NNS
as/IN
well/RB
as/IN
creating/VBG
a/DT
network/NN
among/IN
these/DT
biobanks/NNS
,/,
including/VBG
National/JJ
Biobank/NNP
of/IN
Korea/NN
(/(
NBK/NN
)/)
,/,
which/WDT
is/VBZ
the/DT
largest/JJS
national/JJ
biorepository/JJ
in/IN
Korea/NN
,/,
located/JJ
in/IN
Osong/JJ
,/,
the/DT
central/JJ
region/NN
in/IN
South/DT
Korea/NN
[/(
13/CD
,/,
14/CD
]/)
./.
====================
NBK/NN
provides/VBZ
essential/JJ
biospecimens/NNS
to/TO
scientific/JJ
researchers/NNS
by/IN
collecting/VBG
,/,
maintaining/VBG
,/,
and/CC
distributing/VBG
DNA/NN
and/CC
serum/NN
,/,
plasma/NN
,/,
and/CC
lymphoblastoid/JJ
cell/NN
line/NN
(/(
LCL/NN
)/)
./.
====================
A/DT
new/JJ
building/VBG
for/IN
NBK/NN
,/,
the/DT
largest/JJS
in/IN
Asia/NN
,/,
was/VBD
constructed/VBN
in/IN
April/NN
,/,
2012/CD
at/IN
Osong/JJ
,/,
Chungcheongbuk-do/NN
,/,
Korea/NN
./.
====================
The/DT
three-story/JJ
building/VBG
,/,
including/VBG
storage/NN
rooms/NNS
that/DT
can/MD
contain/VB
26/CD
million/NN
vials/NNS
of/IN
biospecimens/NNS
,/,
was/VBD
constructed/VBN
./.
====================
The/DT
structure/NN
also/RB
has/VBZ
laboratories/NNS
,/,
an/DT
auditorium/NN
,/,
and/CC
so/RB
on/IN
./.
====================
The/DT
budget/NN
for/IN
the/DT
project/JJ
was/VBD
secured/VBN
from/IN
the/DT
Korean/JJ
central/JJ
government/JJ
in/IN
2008/CD
,/,
and/CC
the/DT
construction/NN
was/VBD
started/VBN
in/IN
2010/CD
and/CC
finished/JJ
in/IN
2012/CD
[/(
14/CD
]/)
./.
====================
Over/RB
the/DT
years/NNS
,/,
many/JJ
biobanks/NNS
,/,
including/VBG
17/CD
regional/JJ
biobanks/NNS
,/,
have/VBP
been/VBN
established/VBN
and/CC
are/VBP
moving/VBG
from/IN
a/DT
phase/NN
of/IN
sample/JJ
collection/NN
to/TO
open/JJ
their/PRP$
samples/NNS
for/IN
researches/NNS
./.
====================
There/EX
are/VBP
many/JJ
guidelines/NNS
for/IN
the/DT
management/JJ
of/IN
biobanks/NNS
,/,
such/JJ
as/IN
the/DT
International/JJ
Society/NN
for/IN
Biological/JJ
and/CC
Environmental/JJ
Repositories/NNS
(/(
ISBER/NN
)/)
guideline/NN
and/CC
Organization/NN
for/IN
Economic/JJ
Cooperation/NN
and/CC
Development/NN
(/(
OECD/NN
)/)
[/(
15/CD
]/)
guideline/NN
[/(
16/CD
]/)
./.
====================
ISBER/NN
is/VBZ
the/DT
largest/JJS
international/JJ
forum/NN
that/DT
addresses/VBZ
the/DT
technical/JJ
,/,
legal/JJ
,/,
ethical/JJ
,/,
and/CC
managerial/JJ
issues/NNS
relevant/JJ
to/TO
repositories/NNS
of/IN
biological/JJ
and/CC
environmental/JJ
specimens/NNS
./.
====================
ISBER/NN
has/VBZ
the/DT
``/NN
Best/JJS
Practices/NNS
for/IN
Repositories/Collection/NN
,/,
Storage/JJ
and/CC
Retrieval/NN
of/IN
Human/JJ
Biological/JJ
Materials/NNS
for/IN
Research/NN
./.
''/CD
====================
Also/RB
,/,
ISBER/NN
has/VBZ
introduced/VBN
standard/JJ
PREanalytical/JJ
Coding/JJ
(/(
SPREC/NN
)/)
and/CC
can/MD
be/VB
used/VBN
in/IN
the/DT
biobank/NN
[/(
17/CD
]/)
./.
====================
In/IN
October/NN
2009/CD
,/,
the/DT
OECD/NN
council/NN
adapted/VBN
a/DT
recommendation/NN
for/IN
Human/JJ
Biobanks/NNS
and/CC
Genetic/JJ
Research/NN
Databases/NNS
(/(
HBGRDs/NNS
)/)
./.
====================
The/DT
purpose/NN
of/IN
this/DT
recommendation/NN
suggests/VBZ
guidelines/NNS
for/IN
the/DT
establishment/NN
,/,
management/JJ
,/,
governance/NN
,/,
operation/NN
,/,
access/RB
,/,
use/NN
,/,
and/CC
discontinuation/NN
of/IN
HBGRDs/NNS
,/,
which/WDT
are/VBP
structured/JJ
resources/VBZ
that/DT
can/MD
be/VB
used/VBN
for/IN
the/DT
purpose/NN
of/IN
genetic/JJ
research/NN
./.
====================
The/DT
OECD/NN
Best/JJS
Practice/NN
Guidelines/NNS
for/IN
Biological/JJ
Resource/NN
Centers/NNS
set/NN
out/RP
further/RBR
complementary/JJ
quality/NN
assurance/NN
and/CC
technical/JJ
aspects/NNS
for/IN
the/DT
acquisition/NN
,/,
maintenance/NN
,/,
and/CC
provision/NN
of/IN
high-quality/JJ
biological/JJ
materials/NNS
in/IN
a/DT
secure/JJ
manner/NN
./.
====================
The/DT
standard/JJ
operating/VBG
protocols/NNS
(/(
SOPs/NNS
)/)
,/,
regulations/NNS
,/,
and/CC
management/JJ
for/IN
human/JJ
biospecimens/NNS
are/VBP
important/JJ
./.
====================
DNA/NN
stability/NN
and/CC
DNA/NN
purity/NN
in/IN
clinical/JJ
samples/NNS
are/VBP
essential/JJ
for/IN
correct/JJ
performance/NN
and/CC
interpretation/NN
for/IN
diagnosis/NN
and/CC
research/NN
./.
====================
Generally/RB
,/,
quality/NN
assurance/NN
of/IN
human/JJ
biospecimens/NNS
consists/VBZ
of/IN
a/DT
DNA/NN
stability/NN
test/NN
,/,
DNA/NN
purity/NN
test/NN
,/,
microorganism/NN
contamination/NN
test/NN
,/,
and/CC
cross-contamination/NN
test/NN
./.
====================
All/DT
biospecimens/NNS
collected/JJ
from/IN
the/DT
Korea/NN
Genome/NN
and/CC
Epidemiology/JJ
Study/NN
(/(
KoGES/NN
)/)
in/IN
the/DT
case/NN
of/IN
the/DT
NBK/NN
underwent/JJ
a/DT
DNA/NN
degradation/NN
test/NN
and/CC
purity/NN
test/NN
./.
====================
Ten/CD
percent/JJ
of/IN
biospecimens/NNS
stored/VBD
in/IN
NBK/NN
were/VBD
randomly/RB
chosen/NN
and/CC
tested/VBN
for/IN
the/DT
quality/NN
assurance/NN
test/NN
to/TO
ensure/VB
the/DT
high/JJ
quality/NN
of/IN
DNA/NN
extracted/VBN
from/IN
the/DT
biospecimens/NNS
and/CC
to/TO
check/VB
contamination/NN
by/IN
microorganisms/NNS
./.
====================
The/DT
quality/NN
of/IN
DNA/NN
is/VBZ
important/JJ
for/IN
genetic/JJ
research/NN
,/,
such/JJ
as/IN
genome-wide/JJ
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
and/CC
whole-genome/JJ
sequencing/NN
(/(
WGS/NN
)/)
./.
====================
In/IN
general/JJ
,/,
pure/JJ
preparations/NNS
of/IN
DNA/NN
and/CC
RNA/NN
have/VBP
an/DT
OD260/OD280/CD
of/IN
1.8/CD
and/CC
2.0/CD
respectively/RB
./.
====================
LCL/NN
quality/NN
assurance/NN
was/VBD
also/RB
conducted/VBD
,/,
and/CC
10/CD
%/NN
of/IN
the/DT
stocked/JJ
LCL/NN
was/VBD
randomly/RB
selected/VBN
to/TO
undergo/VB
survival/NN
rate/NN
investigation/NN
and/CC
cross-contamination/NN
test/NN
in/IN
the/DT
NBK/NN
[/(
13/CD
]/)
./.
====================
Informed/VBN
consent/JJ
is/VBZ
getting/VBG
a/DT
patient/NN
to/TO
sign/JJ
a/DT
written/JJ
consent/JJ
form/VBP
and/CC
is/VBZ
the/DT
process/NN
of/IN
communication/NN
between/IN
a/DT
patient/NN
and/CC
a/DT
medical/JJ
doctor/NN
./.
====================
In/IN
medical/JJ
diagnosis/NN
and/CC
treatment/NN
,/,
including/VBG
invasive/JJ
procedures/NNS
,/,
a/DT
doctor/NN
or/CC
a/DT
researcher/JJ
must/MD
give/VB
sufficient/JJ
information/NN
to/TO
the/DT
patient/NN
./.
====================
Informed/VBN
consent/JJ
can/MD
be/VB
given/VBN
based/VBN
on/IN
a/DT
clear/JJ
understanding/NN
of/IN
the/DT
process/NN
,/,
implications/NNS
,/,
and/CC
consequences/NNS
of/IN
an/DT
action/NN
./.
====================
The/DT
consent/JJ
process/NN
should/MD
include/VB
sufficient/JJ
explanation/NN
about/RB
how/WRB
individual/JJ
information/NN
would/MD
be/VB
handled/VBN
[/(
18/CD
]/)
./.
====================
The/DT
consent/JJ
process/NN
includes/VBZ
the/DT
impact/NN
of/IN
research/NN
results/NNS
on/IN
the/DT
lives/NNS
of/IN
participants/NNS
,/,
their/PRP$
families/NNS
,/,
and/CC
their/PRP$
communities/NNS
[/(
19/CD
]/)
./.
====================
Explanations/NNS
should/MD
be/VB
on/IN
confidentiality/NN
,/,
participants/NNS
'/``
rights/NNS
of/IN
withdrawal/NN
,/,
and/CC
specifications/NNS
[/(
20/CD
]/)
./.
====================
Due/IN
to/TO
the/DT
difficulties/NNS
of/IN
securing/VBG
specific/JJ
informed/VBN
consent/NN
,/,
broad/JJ
consent/JJ
is/VBZ
a/DT
more/RBR
general/JJ
form/VBP
of/IN
consent/JJ
in/IN
which/WDT
individuals/NNS
agree/CD
to/TO
have/VB
their/PRP$
biosamples/NNS
and/CC
personal/JJ
information/NN
collected/JJ
and/CC
stored/VBD
in/IN
the/DT
biobank/NN
and/CC
for/IN
future/JJ
,/,
unspecified/JJ
research/NN
[/(
21/CD
]/)
./.
====================
Further/RB
issues/NNS
have/VBP
been/VBN
discussed/VBN
recently/RB
,/,
such/JJ
as/IN
privacy/RB
,/,
confidentiality/NN
and/CC
data/NNS
protection/NN
,/,
controlling/VBG
data/NNS
access/VBP
,/,
accessibility/NN
to/TO
biospecimens/NNS
,/,
benefit/IN
sharing/VBG
,/,
commercialization/NN
,/,
intellectual/JJ
property/NN
rights/NNS
,/,
and/CC
genetic/JJ
discrimination/NN
[/(
22/CD
]/)
./.
====================
In/IN
order/NN
to/TO
ensure/VB
bioethics/NNS
and/CC
bioethical/JJ
safety/NN
in/IN
the/DT
life/NN
sciences/NNS
and/CC
biotechnologies/NNS
,/,
each/DT
of/IN
the/DT
institutions/NNS
should/MD
set/NN
up/IN
its/PRP$
own/JJ
Institutional/JJ
Review/NN
Board/JJ
(/(
IRB/NN
)/)
./.
====================
When/WRB
a/DT
genetic/JJ
testing/NN
or/CC
research/NN
institution/NN
obtains/NNS
written/RB
informed/VBN
consent/NN
from/IN
a/DT
test/NN
subject/JJ
concerning/VBG
the/DT
use/NN
of/IN
specimens/NNS
for/IN
research/NN
purposes/NNS
,/,
it/PRP
may/MD
provide/VB
the/DT
specimens/NNS
to/TO
either/CC
a/DT
person/NN
conducting/VBG
research/NN
on/IN
genes/NNS
or/CC
an/DT
institution/NN
licensed/VBN
to/TO
open/JJ
a/DT
biobank/NN
in/IN
Korea/NN
[/(
1/CD
]/)
./.
====================
In/IN
Korea/NN
,/,
the/DT
Bioethics/NNS
and/CC
Safety/NN
Act/NN
was/VBD
completely/RB
revised/VBD
to/TO
reinforce/VB
research/NN
ethics/NNS
,/,
including/VBG
biobanks/NNS
,/,
and/CC
the/DT
law/NN
took/VBD
effect/NN
in/IN
2013/CD
./.
====================
The/DT
number/NN
of/IN
biobanks/NNS
within/IN
university-affiliated/JJ
hospitals/NNS
will/MD
increase/VB
./.
====================
This/DT
law/NN
encourages/VBZ
biobanks/NNS
to/TO
strengthen/JJ
ethical/JJ
use/NN
of/IN
biospecimens/NNS
,/,
and/CC
the/DT
law/NN
assesses/NNS
biobanks/NNS
'/``
responsibility/NN
to/TO
obtain/VB
informed/VBN
consent/NN
from/IN
donors/NNS
and/CC
is/VBZ
supervised/VBN
by/IN
the/DT
IRB/NN
./.
====================
The/DT
law/NN
also/RB
encourages/VBZ
individual/JJ
researchers/NNS
to/TO
deposit/VB
and/CC
use/NN
biospecimens/NNS
at/IN
any/DT
biobank/NN
instead/RB
of/IN
collecting/JJ
their/PRP$
own/JJ
sample/NN
collection/NN
and/CC
distribution/NN
processes/NNS
[/(
1/CD
,/,
14/CD
]/)
./.
====================
Many/JJ
biobanks/NNS
have/VBP
policies/NNS
for/IN
the/DT
distribution/NN
of/IN
biospecimens/NNS
and/CC
data/NNS
./.
====================
For/IN
example/NN
,/,
there/EX
is/VBZ
a/DT
guideline/NN
to/TO
distribute/JJ
biospecimens/NNS
in/IN
the/DT
National/JJ
Health/NN
and/CC
Nutrition/NN
Examination/NN
Survey/NN
(/(
NHANES/NNS
)/)
,/,
which/WDT
is/VBZ
a/DT
program/NN
of/IN
studies/NNS
designed/VBD
to/TO
assess/VB
the/DT
health/NN
and/CC
nutritional/JJ
status/NN
of/IN
adults/NNS
and/CC
children/NN
in/IN
the/DT
United/JJ
States/NNS
./.
====================
NHANES/NNS
's/POS
biospecimens/NNS
are/VBP
representative/JJ
samples/NNS
of/IN
Americans/NNS
and/CC
should/MD
not/RB
be/VB
used/VBN
for/IN
the/DT
independent/JJ
case-control/JJ
study/NN
,/,
and/CC
1individual/JJ
vial/JJ
must/MD
be/VB
stored/VBN
permanently/RB
./.
====================
All/DT
proposals/NNS
for/IN
the/DT
use/NN
of/IN
NHANES/NN
samples/NNS
are/VBP
evaluated/VBN
by/IN
a/DT
technical/JJ
panel/NN
for/IN
scientific/JJ
merit/NN
and/CC
by/IN
the/DT
NHANES/NN
Ethics/NNS
Review/NN
Board/JJ
(/(
ERB/NN
)/)
./.
====================
To/TO
determine/VB
if/IN
this/DT
limited/JJ
resource/NN
should/MD
be/VB
used/VBN
in/IN
the/DT
proposed/JJ
projects/NNS
,/,
a/DT
technical/JJ
panel/NN
will/MD
evaluate/VB
the/DT
public/JJ
health/NN
significance/NN
and/CC
scientific/JJ
merit/NN
of/IN
the/DT
proposed/JJ
research/NN
./.
====================
Distribution/NN
of/IN
a/DT
0.5-mL/JJ
sample/NN
is/VBZ
available/JJ
once/RB
,/,
and/CC
after/IN
finishing/VBG
the/DT
research/NN
,/,
the/DT
remaining/VBG
samples/NNS
are/VBP
abandoned/VBN
,/,
or/CC
remnants/NNS
more/RBR
than/IN
0.3/CD
mL/NNS
should/MD
be/VB
returned/VBN
to/TO
NHANES/NN
;/:
third-party/DT
biospecimen/NNS
transfer/NN
is/VBZ
not/RB
permitted/VBN
./.
====================
Researchers/NNS
who/WP
received/VBD
specimens/NNS
must/MD
submit/VB
the/DT
result/NN
of/IN
the/DT
analysis/NN
,/,
such/JJ
as/IN
quality/NN
control/NN
and/CC
analytical/JJ
methods/NNS
with/IN
documents/NNS
,/,
to/TO
the/DT
National/JJ
Center/NN
for/IN
Health/NN
Statistics/NNS
(/(
NCHS/NN
)/)
./.
====================
Surplus/NN
data/NNS
without/IN
DNA/NN
analysis/NN
results/VBZ
would/MD
be/VB
opened/VBN
in/IN
the/DT
website/JJ
and/CC
given/VBN
a/DT
period/NN
of/IN
3/CD
months/NNS
for/IN
analysis/NN
./.
====================
A/DT
researcher/JJ
's/POS
intellectual/JJ
property/NN
rights/NNS
are/VBP
not/RB
permitted/VBN
because/IN
of/IN
research/NN
for/IN
public/JJ
health/NN
(/(
http/NN
:/:
//www/cdc/gov/nchs/nhanes.htm/JJ
)/)
./.
====================
The/DT
Prostate/JJ
,/,
Lung/NN
,/,
Colorectal/JJ
,/,
and/CC
Ovarian/JJ
Cancer/NN
Screening/JJ
Trial/JJ
(/(
PLCO/NN
)/)
biorepository/JJ
in/IN
the/DT
United/JJ
States/NNS
has/VBZ
2.9/CD
million/NN
biological/JJ
samples/NNS
,/,
including/VBG
blood/NN
,/,
and/CC
researchers/NNS
can/MD
use/VB
samples/NNS
and/CC
data/NNS
through/IN
the/DT
process/NN
of/IN
peer/NN
review/NN
./.
====================
Researchers/NNS
can/MD
submit/VB
summarized/VBD
proposals/NNS
to/TO
the/DT
PLCO/NN
,/,
and/CC
the/DT
chosen/NN
research/NN
is/VBZ
recommended/VBN
for/IN
full/JJ
research/NN
proposals/NNS
and/CC
submissions/NNS
are/VBP
available/JJ
twice/RB
in/IN
June/July/NN
or/CC
December/January/JJ
annually/RB
./.
====================
The/DT
review/NN
process/NN
takes/VBZ
4/CD
or/CC
6/CD
months/NNS
./.
====================
Researchers/NNS
with/IN
approved/JJ
proposals/NNS
should/MD
submit/VB
IRB/NN
approval/JJ
documents/VBZ
and/CC
contract/VB
the/DT
Material/JJ
Transfer/NN
Agreement/JJ
(/(
MTA/NN
)/)
mutually/RB
,/,
and/CC
biospecimens/NNS
are/VBP
distributed/VBN
to/TO
researchers/NNS
when/WRB
approved/VBN
;/:
researchers/NNS
should/MD
report/VB
experimental/JJ
results/NNS
to/TO
Information/NN
Management/JJ
Systems/NNS
(/(
IMS/NN
)/)
(/(
http/NN
:/:
//www.plcostars.com/IN
)/)
./.
====================
At/IN
present/JJ
,/,
distribution/NN
of/IN
biospecimens/NNS
is/VBZ
available/JJ
to/TO
Korean/JJ
researchers/NNS
irrespective/JJ
of/IN
research/NN
funds/VBZ
,/,
and/CC
the/DT
distribution/NN
for/IN
data/NNS
is/VBZ
accessible/JJ
to/TO
Korean/JJ
researchers/NNS
without/IN
financial/JJ
sponsors/NNS
in/IN
Korean/JJ
biobanks/NNS
./.
====================
All/DT
proposals/NNS
for/IN
distribution/NN
of/IN
data/NNS
and/CC
biospecimens/NNS
should/MD
be/VB
reviewed/VBN
and/CC
be/VB
approved/VBN
by/IN
the/DT
IRB/NN
belonging/VBG
to/TO
an/DT
institute/JJ
prior/JJ
to/TO
submission/NN
./.
====================
Opened/JJ
data/NNS
and/CC
biospecimens/NNS
for/IN
distribution/NN
in/IN
the/DT
NBK/NN
are/VBP
shown/VBN
in/IN
Tables/NNS
2/CD
and/CC
3/CD
./.
====================
First/RB
of/IN
all/DT
,/,
researchers/NNS
who/WP
want/JJ
to/TO
receive/JJ
the/DT
data/NNS
and/CC
biospecimens/NNS
have/VBP
to/TO
submit/VB
the/DT
application/NN
document/VBP
to/TO
the/DT
NBK/NN
./.
====================
The/DT
submitted/VBN
documents/VBZ
will/MD
be/VB
reviewed/VBN
,/,
and/CC
a/DT
board/JJ
meeting/VBG
for/IN
distribution/NN
is/VBZ
held/RB
monthly/RB
;/:
distribution/NN
of/IN
work/NN
for/IN
the/DT
approved/JJ
application/NN
will/MD
be/VB
performed/VBN
approximately/RB
within/IN
one/CD
or/CC
two/CD
months/NNS
from/IN
submission/NN
of/IN
the/DT
application/NN
documents/VBZ
for/IN
distribution/NN
./.
====================
NBK/NN
is/VBZ
planning/JJ
a/DT
website/JJ
for/IN
the/DT
distribution/NN
process/NN
./.
====================
Most/JJS
of/IN
the/DT
distributed/VBN
biospecimens/NNS
are/VBP
DNA/NN
samples/NNS
in/IN
the/DT
NBK/NN
,/,
and/CC
a/DT
few/JJ
body/NN
fluid/NN
samples/NNS
,/,
including/VBG
sera/NNS
and/CC
plasma/NN
,/,
were/VBD
distributed/VBN
./.
====================
According/VBG
to/TO
the/DT
advancement/JJ
of/IN
the/DT
technology/NN
,/,
the/DT
minimum/JJ
quantity/NN
for/IN
clinical/JJ
examination/NN
and/CC
for/IN
the/DT
analysis/NN
of/IN
metabolites/NNS
is/VBZ
diminishing/VBG
./.
====================
However/RB
,/,
sera/NNS
and/CC
plasma/NN
are/VBP
very/RB
limited/JJ
resources/VBZ
,/,
and/CC
political/JJ
decisions/NNS
and/CC
long-term/JJ
planning/VBG
for/IN
the/DT
use/NN
of/IN
body/NN
fluid/NN
samples/NNS
will/MD
be/VB
needed/VBN
[/(
12/CD
]/)
./.
====================
In/IN
2000/CD
,/,
following/VBG
the/DT
HGP/NN
,/,
biological/JJ
research/NN
moved/JJ
into/IN
the/DT
so-called/JJ
genomic/JJ
era/NN
./.
====================
Diseases/NNS
have/VBP
been/VBN
studied/VBN
by/IN
identifying/VBG
genes/NNS
and/CC
their/PRP$
specific/JJ
function/NN
and/CC
understanding/VBG
the/DT
role/NN
played/VBD
by/IN
genetics/NNS
in/IN
the/DT
beginning/VBG
and/CC
prognosis/NN
of/IN
diseases/NNS
,/,
and/CC
an/DT
advanced/JJ
world/NN
of/IN
medicine/JJ
,/,
known/VBN
as/IN
``/RB
personalized/VBN
medicine/JJ
,/,
''/NNP
has/VBZ
been/VBN
initiated/VBN
[/(
5/CD
]/)
./.
====================
Accessibility/NN
to/TO
human/JJ
specimens/NNS
and/CC
data/NNS
for/IN
the/DT
purposes/NNS
of/IN
research/NN
is/VBZ
important/JJ
for/IN
realms/NNS
,/,
such/JJ
as/IN
genomics/NNS
,/,
proteomics/NNS
,/,
metabolomics/NNS
,/,
molecular/JJ
imaging/NN
,/,
and/CC
nanotechnology/NN
[/(
23/CD
]/)
./.
====================
There/EX
are/VBP
genetic/JJ
factors/NNS
that/WDT
affect/VBP
susceptibility/NN
to/TO
common/JJ
diseases/NNS
[/(
24/CD
]/)
./.
====================
These/DT
diseases/NNS
may/MD
have/VB
several/JJ
genetic/JJ
risk/NN
factors/NNS
that/WDT
influence/VBP
each/DT
other/JJ
,/,
and/CC
interact/VBP
with/IN
the/DT
environment/NN
,/,
and/CC
this/DT
has/VBZ
spurred/VBN
the/DT
development/NN
of/IN
large-scale/JJ
biobanking/VBG
projects/NNS
to/TO
identify/VB
susceptible/JJ
genes/NNS
[/(
25/CD
]/)
./.
====================
Despite/IN
intensive/JJ
research/NN
over/IN
the/DT
last/JJ
decade/NN
,/,
most/JJS
of/IN
the/DT
genetic/JJ
basis/NN
of/IN
common/JJ
human/JJ
diseases/NNS
remains/VBZ
unknown/JJ
./.
====================
The/DT
identification/NN
of/IN
meaningful/JJ
genetic/JJ
variants/NNS
,/,
genes/NNS
,/,
and/CC
pathways/NNS
involved/VBN
in/IN
special/JJ
diseases/NNS
offers/VBZ
a/DT
potential/JJ
route/JJ
to/TO
new/JJ
therapies/NNS
,/,
improved/VBD
diagnosis/NN
,/,
and/CC
better/RBR
disease/NN
prevention/NN
./.
====================
For/IN
some/DT
time/NN
,/,
it/PRP
has/VBZ
been/VBN
hoped/VBN
that/DT
the/DT
advent/JJ
of/IN
GWASs/NNS
would/MD
provide/VB
a/DT
successful/JJ
new/JJ
tool/NN
for/IN
solving/JJ
the/DT
genetic/JJ
basis/NN
of/IN
many/JJ
of/IN
these/DT
common/JJ
causes/VBZ
of/IN
human/JJ
morbidity/NN
and/CC
mortality/NN
./.
====================
Advances/NNS
in/IN
sequencing/NN
technology/NN
enabled/VBD
us/PRP
to/TO
sequence/NN
the/DT
whole/JJ
human/JJ
genome/NN
[/(
26/CD
,/,
27/CD
]/)
./.
====================
The/DT
use/NN
of/IN
WGS/NN
of/IN
large/JJ
patient/NN
cohorts/NNS
is/VBZ
a/DT
much-needed/JJ
approach/NN
in/IN
researching/VBG
complex/NN
traits/VBZ
;/:
it/PRP
is/VBZ
still/RB
being/VBG
ruled/VBN
out/IN
to/TO
detect/VB
low-frequency/NN
genetic/JJ
variants/NNS
,/,
due/JJ
to/TO
its/PRP$
high/JJ
costs/NNS
[/(
28/CD
,/,
29/CD
]/)
./.
====================
Among/IN
the/DT
new/JJ
and/CC
emerging/VBG
fields/NNS
of/IN
research/NN
is/VBZ
proteomics/NNS
,/,
the/DT
study/NN
of/IN
the/DT
full/JJ
set/NN
of/IN
proteins/NNS
encoded/VBN
by/IN
the/DT
genome/NN
./.
====================
Also/RB
,/,
proteomics/NNS
is/VBZ
strongly/RB
associated/VBN
with/IN
the/DT
discovery/NN
phase/NN
,/,
the/DT
first/JJ
step/NN
in/IN
the/DT
process/NN
chain/NN
to/TO
create/VB
diagnostic/JJ
content/NN
[/(
30/CD
]/)
./.
====================
Due/IN
to/TO
the/DT
increased/VBN
demands/VBZ
on/IN
qualified/VBN
biospecimens/NNS
for/IN
research/NN
,/,
the/DT
number/NN
of/IN
biobanks/NNS
has/VBZ
significantly/RB
increased/VBD
recently/RB
./.
====================
By/IN
virtue/NN
of/IN
the/DT
advancements/NNS
in/IN
bioinformatics/NNS
and/CC
biotechnology/NN
,/,
storing/VBG
biospecimens/NNS
and/CC
data/NNS
on/IN
a/DT
large/JJ
scale/JJ
requires/VBZ
that/DT
biobanks/VBZ
harmonize/VBP
biobank/NN
processes/NNS
and/CC
regulations/NNS
[/(
5/CD
]/)
./.
====================
Most/JJS
biobanks/NNS
did/VBD
their/PRP$
best/JJS
to/TO
secure/VB
more/RBR
biospecimens/NNS
at/IN
the/DT
inception/NN
of/IN
the/DT
foundation/NN
and/CC
comparably/RB
distribution/NN
rate/NN
for/IN
the/DT
researchers/NNS
is/VBZ
low/JJ
./.
====================
According/VBG
to/TO
a/DT
first/JJ
survey/NN
of/IN
456/CD
biobank/NN
managers/NNS
in/IN
the/DT
United/JJ
States/NNS
,/,
nearly/RB
70/CD
%/NN
of/IN
those/DT
questioned/VBN
were/VBD
concerned/VBN
with/IN
underuse/JJ
of/IN
the/DT
samples/NNS
in/IN
their/PRP$
repositories/NNS
[/(
31/CD
]/)
./.
====================
Therefore/RB
,/,
many/JJ
biobankers/NNS
are/VBP
trying/VBG
to/TO
advertise/VB
their/PRP$
biospecimens/NNS
to/TO
researchers/NNS
in/IN
regional/JJ
academic/JJ
societies/NNS
./.
====================
Like/IN
the/DT
United/JJ
States/NNS
,/,
the/DT
NBK/NN
has/VBZ
faced/VBN
a/DT
similar/JJ
situation/NN
for/IN
the/DT
underuse/JJ
of/IN
biospecimens/NNS
stored/VBD
in/IN
the/DT
biobank/NN
./.
====================
In/IN
the/DT
first/JJ
phase/NN
of/IN
the/DT
KBP/NN
(/(
2008-2012/CD
)/)
,/,
biobanks/VBZ
concentrated/VBN
on/IN
securing/VBG
facilities/NNS
,/,
such/JJ
as/IN
storage/NN
equipment/JJ
,/,
as/IN
well/RB
as/IN
securing/VBG
manpower/VBP
and/CC
funding/VBG
for/IN
biobanks/NNS
./.
====================
However/RB
,/,
in/IN
the/DT
second/JJ
phase/NN
(/(
2013-2015/CD
)/)
,/,
more/RBR
R/NN
&/CC
D/NN
projects/NNS
are/VBP
needed/VBN
that/DT
support/VBP
clinicians/NNS
,/,
so/RB
that/IN
it/PRP
will/MD
be/VB
possible/JJ
to/TO
gather/RBR
resources/VBZ
with/IN
more/RBR
information/NN
./.
====================
For/IN
maximizing/VBG
the/DT
value/NN
of/IN
biospecimens/NNS
,/,
consistency/NN
in/IN
the/DT
methods/NNS
by/IN
which/WDT
they/PRP
are/VBP
retrieved/VBN
,/,
processed/VBN
,/,
stored/VBD
,/,
and/CC
transported/VBD
is/VBZ
important/JJ
./.
====================
Ideally/RB
,/,
this/DT
should/MD
involve/VB
the/DT
use/NN
of/IN
agreed/NN
SOPs/NNS
in/IN
general/JJ
[/(
32/CD
]/)
./.
====================
The/DT
other/JJ
issue/NN
in/IN
the/DT
next/JJ
big/NN
step/NN
is/VBZ
automated/VBN
biobanking/VBG
,/,
and/CC
today/RB
's/POS
biobanks/NNS
demand/CC
and/CC
move/VB
toward/IN
automated/JJ
sample/NN
management/JJ
systems/NNS
that/DT
meet/VBP
the/DT
requirements/NNS
for/IN
reliability/NN
,/,
sample/JJ
integrity/NN
,/,
high/JJ
capacity/NN
,/,
and/CC
high/JJ
throughput/NN
./.
====================
Horn/JJ
,/,
the/DT
former/JJ
director/JJ
of/IN
the/DT
Genetic/JJ
Alliance/NN
,/,
demonstrates/VBZ
that/IN
biobanks/VBZ
have/VBP
to/TO
cooperate/VB
together/RB
to/TO
achieve/VB
their/PRP$
mission/NN
,/,
and/CC
standardization/NN
is/VBZ
going/VBG
to/TO
be/VB
important/JJ
for/IN
researchers/NNS
to/TO
get/VB
samples/NNS
from/IN
different/JJ
collections/NNS
;/:
we/PRP
need/VBD
catalogs/NNS
that/DT
say/NN
where/WRB
these/DT
samples/NNS
exist/VBP
[/(
33/CD
]/)
./.
====================
Accreditation/NN
processes/NNS
can/MD
also/RB
be/VB
introduced/VBN
to/TO
biobanks/NNS
for/IN
harmonizing/VBG
collections/NNS
and/CC
encouraging/VBG
use/NN
of/IN
biospecimens/NNS
in/IN
the/DT
biobanks/NNS
,/,
including/VBG
the/DT
KBN/NN
./.
====================
The/DT
NBK/NN
is/VBZ
also/RB
preparing/VBG
an/DT
online/JJ
distribution/NN
portal/JJ
for/IN
the/DT
convenient/JJ
application/NN
of/IN
distribution/NN
to/TO
researchers/NNS
and/CC
preparing/VBG
a/DT
biobank/NN
accreditation/NN
program/NN
;/:
these/DT
will/MD
harmonize/VBP
the/DT
biobanks/NNS
in/IN
Korea/NN
./.
====================
Biobanks/NNS
with/IN
sample/NN
sizes/NNS
â‰¥/CD
200,000/CD
(/(
2012/CD
)/)
====================
Data/NNS
for/IN
distribution/NN
ofthe/DT
National/JJ
Biobank/NN
of/IN
Korea/NN
(/(
as/IN
of/IN
June/JJ
2013/CD
)/)
====================
Biospecimens/NNS
for/IN
distribution/NN
of/IN
the/DT
National/JJ
Biobank/NN
of/IN
Korea/NN
(/(
as/IN
of/IN
June/JJ
2013/CD
)/)
====================
